Bavarian Nordic will no longer work on its immuno-oncology vaccine program to instead focus on infectious disease R&D, with the company’s “record” 2023 sales buoyed by its mpox vaccine Jynneos.
The Danish biotech was working on a Phase I cancer vaccine, dubbed TAEK-VAC, which targets a tumor-associated antigen. The asset was being investigated in subjects with chordoma (tumor in the spine or at the base of the skull) or HER2-positive breast cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.